Quanterix (QTRX) expects to raise $50 million in an initial public offering on Thursday, December 7th, IPO Scoop reports. The company plans to issue 3,300,000 shares at a price of $14.00-$16.00 per share.
In the last year, Quanterix generated $23 million in revenue and had a net loss of $31.4 million. Quanterix has a market-cap of $303.7 million.
J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.
Quanterix provided the following description of their company for its IPO: “We are a life sciences company that has developed a next generation, ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Our platform enables customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. “.
Quanterix was founded in 2007 and has 122 employees. The company is located at 113 Hartwell Avenue, Lexington, MA 02421, US and can be reached via phone at (617) 301-9400 or on the web at http://www.quanterix.com.
What are top analysts saying about Quanterix? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Quanterix and related companies.